ClinicalTrials.Veeva

Menu

Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy

Vertex Pharmaceuticals logo

Vertex Pharmaceuticals

Status and phase

Enrolling
Phase 3

Conditions

Diabetic Peripheral Neuropathic Pain

Treatments

Drug: Suzetrigine
Drug: Placebo (matched to Pregabalin)
Drug: Pregabalin
Drug: Placebo (matched to SUZ)

Study type

Interventional

Funder types

Industry

Identifiers

NCT06628908
VX24-548-110

Details and patient eligibility

About

The purpose of this study is to evaluate the efficacy, safety, and tolerability of Suzetrigine (SUZ) in participants with pain associated with diabetic peripheral neuropathy (DPN).

Enrollment

1,100 estimated patients

Sex

All

Ages

18 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Key Inclusion Criteria:

  • Body weight greater than or equal to (≥) 45 kilogram (kg)
  • Body mass index (BMI) ≥18.0 to less than (<) 40.0 kilogram per meter square (kg/m^2)
  • Diagnosis of diabetes mellitus type 1 or type 2 by glycosylated hemoglobin A1c (HbA1c) ≤9% and the presence of bilateral pain in lower extremities due to DPN
  • Weekly average of daily NPRS score ≥4 and less than or equal to (≤) 9 with limited variation in the 7-day Baseline Period

Key Exclusion Criteria:

  • More than 3 missing daily NPRS scores during the 7-day Baseline Period
  • Participation in a previous study in which the participant received SUZ
  • Any sensory abnormality (excluding DPN) as pre-specified in the protocol

Other protocol defined Inclusion/Exclusion criteria may apply.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Quadruple Blind

1,100 participants in 3 patient groups, including a placebo group

Suzetrigine (SUZ)
Experimental group
Description:
Participants will be randomized to receive SUZ.
Treatment:
Drug: Placebo (matched to Pregabalin)
Drug: Suzetrigine
Pregabalin
Active Comparator group
Description:
Participants will be randomized to receive Pregabalin.
Treatment:
Drug: Placebo (matched to SUZ)
Drug: Pregabalin
Placebo
Placebo Comparator group
Description:
Participants will be randomized to receive placebo matched to SUZ and Pregabalin.
Treatment:
Drug: Placebo (matched to SUZ)
Drug: Placebo (matched to Pregabalin)

Trial contacts and locations

58

Loading...

Central trial contact

Medical Information

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems